AHA: Johnson
Fierce Pharma,
PHILADELPHIA––More than a year after Johnson
PHILADELPHIA––More than a year after Johnson
The new indication covers VTE prophylaxis in acutely ill patients at risk for thromboembolic events without a high bleeding risk.
At last year’s European Society of Cardiology annual meeting, Johnson
MUNICH, Aug. 27, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson